IP Library Granted Patent US 9,611,324
Granted Patent B2
US 9,611,324 · App. 14/687,928 · Granted Apr 4, 2017

Compositions and methods for diagnosing and treating an inflammation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,611,324
App. No.
14/687,928
Granted
Apr 4, 2017
Kind
B2
Abstract

A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Claims (14)

1. A method of treating an autoimmune inflammatory disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated anti-SR-B1 antibody, thereby treating the autoimmune inflammatory disease in the subject, wherein said autoimmune inflammatory disease is selected from the group consisting of colitis, celiac disease and ileitis.

2. The method of claim 1 , wherein said isolated anti-SR-B1 antibody reduces secretion of IL-12 or TNF-α or both in leukocytes.

3. The method of claim 1 , wherein said isolated anti-SR-B1 antibody increases secretion of IL-10 in leukocytes.

4. The method of claim 1 , wherein said isolated anti-SR-B1 antibody reduces secretion of IL-12 or TNF-α or both, and increases secretion of IL-10 in leukocytes.

5. The method of claim 1 , wherein said isolated anti-SR-B1 antibody reduces secretion of IL-12 or TNF-α or both in macrophages.

6. The method of claim 1 , wherein said isolated anti-SR-B1 antibody increases secretion of IL-10 in macrophages.

7. The method of claim 1 , wherein said isolated anti-SR-B1 antibody reduces secretion of IL-12 or TNF-α or both, and increases secretion of IL-10 in macrophages.

8. The method of claim 1 , wherein said isolated anti-SR-B1 antibody reduces secretion of IL-12 or TNF-α or both in T cells.

9. The method of claim 1 , wherein said isolated anti-SR-B1 antibody increases secretion of IL-10 in T cells.

10. The method of claim 1 , wherein said isolated anti-SR-B1 antibody reduces secretion of IL-12 or TNF-α or both, and increases secretion of IL-10 in T cells.

11. The method of claim 1 , wherein said isolated anti-SR-B1 antibody is a human anti-SR-B1 antibody.

12. The method of claim 1 , wherein said autoimmune inflammatory disease is colitis.

13. The method of claim 1 , wherein said autoimmune inflammatory disease is celiac disease.

14. The method of claim 1 , wherein said autoimmune inflammatory disease is ileitis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2018
From: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
To: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Reel/Frame 046493/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2015
From: KARIN, NATHAN; WILDBAUM, GIZI; ANUNU, RACHEL; ZOHAR, YANIV; NETZER, NIR
To: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Reel/Frame 036294/0193 →